Nuveen New Jersey Quality Municipal Income Fund (NXJ) Is At $13.42 Formed Wedge; 2 Analysts Are Bullish Infinity Pharmaceuticals, Inc. (INFI) Last Week

Among 9 analysts covering Infinity Pharmaceutical (NASDAQ:INFI), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Infinity Pharmaceutical had 16 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Outperform” rating by RBC Capital Markets on Friday, August 7. As per Tuesday, June 14, the company rating was downgraded by . Wedbush downgraded Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) rating on Tuesday, March 22. Wedbush has “Underperform” rating and $3 target. The firm has “Hold” rating given on Monday, August 10 by Zacks. The company was initiated on Wednesday, March 2 by FBR Capital. The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has “Hold” rating given on Wednesday, June 15 by Jefferies. Wedbush maintained the shares of INFI in report on Thursday, February 25 with “Neutral” rating. The rating was downgraded by JMP Securities to “Market Perform” on Tuesday, June 14. JMP Securities maintained it with “Market Outperform” rating and $17 target in Wednesday, March 9 report. Wells Fargo upgraded the stock to “Outperform” rating in Thursday, October 12 report. See Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) latest ratings:

12/10/2017 Broker: Wells Fargo Old Rating: Market Perform New Rating: Outperform Upgrade

Nuveen New Jersey Quality Municipal Income Fund (NXJ) formed wedge down with $12.35 target or 8.00% below today’s $13.42 share price. Nuveen New Jersey Quality Municipal Income Fund (NXJ) has $571.49 million valuation. The stock decreased 0.45% or $0.06 during the last trading session, reaching $13.42. About 153,404 shares traded or 96.80% up from the average. Nuveen New Jersey Quality Municipal Income Fund (NYSE:NXJ) has declined 5.26% since January 27, 2017 and is downtrending. It has underperformed by 21.96% the S&P500.

Investors sentiment increased to 1.29 in 2017 Q3. Its up 0.23, from 1.06 in 2017Q2. It increased, as 7 investors sold Nuveen New Jersey Quality Municipal Income Fund shares while 7 reduced holdings. 6 funds opened positions while 12 raised stakes. 2.92 million shares or 0.91% less from 2.94 million shares in 2017Q2 were reported. Wells Fargo & Company Mn stated it has 760,597 shares or 0% of all its holdings. Estabrook Management invested in 6,151 shares. Advisory Svcs Network invested 0% of its portfolio in Nuveen New Jersey Quality Municipal Income Fund (NYSE:NXJ). Geode Cap Limited holds 0% in Nuveen New Jersey Quality Municipal Income Fund (NYSE:NXJ) or 77,802 shares. The Illinois-based Rmb Cap Management Limited Liability Com has invested 0% in Nuveen New Jersey Quality Municipal Income Fund (NYSE:NXJ). Guggenheim Ltd Limited Liability Company, Illinois-based fund reported 403,916 shares. Sit Inv Associates holds 223,758 shares. Janney Montgomery Scott Ltd Liability Corp invested in 0% or 19,690 shares. Royal Comml Bank Of Canada reported 0% in Nuveen New Jersey Quality Municipal Income Fund (NYSE:NXJ). Landscape Mngmt Limited Co accumulated 82,072 shares. Private Advisor Grp Limited Liability Company stated it has 0.01% of its portfolio in Nuveen New Jersey Quality Municipal Income Fund (NYSE:NXJ). Brave Asset Mgmt Incorporated has 16,983 shares for 0.12% of their portfolio. First Manhattan Comm owns 0% invested in Nuveen New Jersey Quality Municipal Income Fund (NYSE:NXJ) for 13,138 shares. Highlander Cap Management stated it has 0.02% in Nuveen New Jersey Quality Municipal Income Fund (NYSE:NXJ). The New York-based Tortoise Inv Mgmt Ltd Com has invested 0.13% in Nuveen New Jersey Quality Municipal Income Fund (NYSE:NXJ).

Investors sentiment decreased to 0.47 in 2017 Q3. Its down 0.16, from 0.63 in 2017Q2. It fall, as 15 investors sold Infinity Pharmaceuticals, Inc. shares while 23 reduced holdings. 6 funds opened positions while 12 raised stakes. 27.30 million shares or 18.05% less from 33.31 million shares in 2017Q2 were reported. State Street accumulated 67,405 shares or 0% of the stock. Vanguard Gp Incorporated holds 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 2.35 million shares. Geode Capital Ltd Llc has invested 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Jacobs Levy Equity invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Rock Springs Management Ltd Partnership, a Maryland-based fund reported 270,000 shares. Federated Invsts Pa holds 0% or 3,876 shares in its portfolio. Citadel Advsr Limited Liability accumulated 0% or 10,590 shares. Dimensional Fund Lp holds 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 90,953 shares. Blair William And Company Il has invested 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). National Bank Of New York Mellon Corp holds 0% or 45,985 shares. Qs Ltd Liability holds 0% or 182,380 shares. Acadian Asset Limited Liability Co owns 36,984 shares or 0% of their US portfolio. Bvf Il accumulated 1.33% or 7.87 million shares. Two Sigma Securities Ltd Liability Corporation holds 0% or 20,279 shares. Tortoise Inv Ltd Llc stated it has 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI).

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $105.99 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Since October 3, 2017, it had 1 insider purchase, and 0 insider sales for $2.01 million activity. $2.01M worth of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) was bought by BVF PARTNERS L P/IL on Tuesday, October 3.